Henan International Joint Laboratory for Nuclear Protein Regulation
Introduction: Henan International Joint Laboratory for Nuclear Protein Regulation was established in December 2017. The director of the laboratory, Prof. Xinying, Ji, is the vice president of Henan Medical School and the doctoral supervisor at the School of Basic Medical Science, Henan University. He has served as a postdoctoral researcher and the assistant professor at Harvard Medical School for nearly ten years. The research group has been approved for 20 projects of National Natural Science Foundation of China and 21 patents. It has published nearly 120 SCI papers and the citation rate has reached more than 3,000 times. The team has successively recruited more than 80 full-time master students, 8 foreign doctoral students, 9 master students, 2 postdoctoral fellows and 15 doctoral students have been recruited by well-known universities.
Research Fields: 1.Functional research and development of novel nuclear protein—PCNP. 2.Research and application of perylene bisimide derivative molecules. 3. The therapeutic mechanism of hydrogen sulfide in tumor and other diseases. 4. Molecular mechanisms of infection-induced diaphragm weakness.
Prospects: The laboratory will fully develop and utilize these three molecules: PCNP, perylene bisimide derivative molecules and H2S to make major breakthroughs in the pathogenesis, diagnosis, treatment and prevention of certain tumors (such as liver cancer, lung cancer, and esophageal cancer). The laboratory will hold the forum on nuclear protein and tumor research, invite renowned experts to promote the research , strengthen cooperation and communication with other scholars so as to create a first-class “nuclear protein research center” with international influence in Henan province.
Website: https://pcnp.henu.edu.cn/
Henan Provincial Strategic Alliance of Industrial Technology Innovation for Precision Medicine against Tumor
Introduction: Henan Provincial Strategic Alliance of Industrial Technology Innovation for Precision Medicine against Tumor is one of the most professional medical alliances led by the Professor Xinying, Ji, the director of Henan International Joint Laboratory for Nuclear Protein Regulation. The alliance will unite some influential biotech companies to carry out the collaboration and integration of tumor precision diagnosis and treatment resources with the help of the basic research platform and international R&D team of Henan University. Since 2020, the alliance has established the all-round Alliance Council, Alliance Expert Council and Executive Committee, laying a solid foundation for the development of the alliance in the future.
Aims: The goal of the alliance is to promote the exploration of tumor molecular diagnostic markers, the establishment of methods of tumor gene and molecular detection, the preparation of therapeutic antibodies, the development of detection technology of molecular pathology and the practice of third-party testing, etc. And the alliance aims at promoting the earlier diagnosis and treatment of tumor, improving the survival rate of patients and contributing to the establishment of a more healthy world.
Prospects: The alliance will integrate various resources, promote the effective integration of Industry, University and Research (IUR) and work together to advance the development of tumor diagnosis and treatment industry. The alliance will set up an all-round platform to expand the market for tumor diagnosis and treatment. It also intends to provide all-round assistance in clinical trials, the collaboration of scientific research, project consultation, financing and incubation of drugs and devices of tumor diagnosis and treatment.